According to Cognitive Market Research, the global Antibody Conjugates Drug market size was USD 9825.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.50% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 3930.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2947.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 2259.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 491.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 196.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.
The breast cancer category is the fastest growing segment of the Antibody Conjugates Drug industry
